CORONA REMEDIES LIMITED Peer Comparison
CORONA · Healthcare · Current price ₹2,048
Peers tracked
11
CORONA REMEDIES LIMITED P/E
67.8x
Sector
Healthcare
CORONA REMEDIES LIMITED vs peers
| Company | Price | P/E | Market cap (Cr) |
|---|---|---|---|
| SUN PHARMACEUTICAL IND L | ₹1,929 | 39.1x | 4,63,480 |
| DIVI S LABORATORIES LTD | ₹9,165 | 69.1x | 2,44,762 |
| TORRENT PHARMACEUTICALS L | ₹4,965.5 | 72.9x | 1,90,640 |
| ZYDUS LIFESCIENCES LTD | ₹1,167.8 | 22.0x | 1,15,132 |
| CIPLA LTD | ₹1,423 | 30.3x | 1,14,134 |
| LAURUS LABS LIMITED | ₹1,861.6 | 92.8x | 1,00,714 |
| MANKIND PHARMA LIMITED | ₹2,356.5 | 53.7x | 98,780 |
| LUPIN LIMITED | ₹2,153 | 20.6x | 98,550 |
| DR. REDDY S LABORATORIES | ₹1,171 | 26.8x | 96,335 |
| AUROBINDO PHARMA LTD | ₹1,683.3 | 25.9x | 94,834 |
| CORONA REMEDIES LIMITED | ₹2,033.3 | 66.5x | 12,447 |
CORONA REMEDIES LIMITED versus its peers
CORONA REMEDIES LIMITED operates in the Healthcare space alongside 11 tracked peers. Comparing valuation multiples within a sector is far more meaningful than in isolation — a P/E of 67.8x may be cheap in one industry and expensive in another.
More on CORONA REMEDIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.